GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK) Files An 8-K Submission of Matters to a Vote of Security Holders
GenMark Diagnostics, Inc. (“GenMark”) held its 2019 Annual Meeting of Stockholders on May 31, 2019 (the “Annual Meeting”), at which a total of 50,733,521 shares of GenMark common stock, or approximately 89% of the shares entitled to vote, were represented in person or by valid proxies. A description of each matter voted upon at the Annual Meeting is described in detail in GenMark’s definitive proxy statement filed with the Securities and Exchange Commission on April 17, 2019. Set forth below are final voting results for the three proposals that were subject to a vote of GenMark’s stockholders at the Annual Meeting.
The following individuals are continuing directors with terms expiring at GenMark’s 2020 Annual Meeting of Stockholders: Daryl J. Faulkner and James Fox, Ph.D.
The following individuals are continuing directors with terms expiring at GenMark’s 2021 Annual Meeting of Stockholders: Hany Massarany and Kevin C. O’Boyle.
No other matters were presented for stockholder approval at the Annual Meeting.
About GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK)
GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States. It has developed and intends to commercially launch its sample-to-answer ePlex instrument and its associated diagnostic tests, which it collectively refers to as its ePlex system, in Europe and the United States. It operates in the development, manufacturing, sales and support of instruments and molecular tests based on its eSensor detection technology segment. Over four of its diagnostic tests, which run on its XT-8 instrument, have received United States Food and Drug Administration clearance, including Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, Thrombophilia Risk Test and Respiratory Viral Panel.
